{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:40:54Z","timestamp":1793187654252,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Evaluating esophageal cancer (EC) response to neoadjuvant radiochemotherapy (NARC) has been challenging, but photon-counting CT (PCCT) provides multiparametric data, including iodine concentration (IC), which can be utilized for evaluation. This study explored the relationship between IC and histopathological features of EC, assessing its role in predicting NARC responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Of 105 patients with EC, 85 (67 men; mean age 66.0\u2009\u00b1\u200911.0 years) met the inclusion criteria and underwent PCCT scans during the portal venous phase. Normalized iodine concentration (NIC) was calculated, and tumor characteristics, including stage, grade, and lymphovascular invasion, were analyzed. Statistical analyses included Mann\u2013Whitney U tests, sensitivity, specificity, and area under the curve (AUC) calculations. Interobserver reliability of NIC measurements was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Interobserver reliability for NIC was excellent (ICC\u2009=\u20090.99 for all tumors,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). In adenocarcinoma, NIC was lower in good therapy responders (Becker 1a\/1b: 0.40\u2009\u00b1\u20090.13) than poor responders (Becker 2\/3: 0.51\u2009\u00b1\u20090.12,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). An NIC cutoff \u2264\u20090.41 predicted good regression (OR\u2009=\u20094.77,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03; AUC\u2009=\u20090.704, sensitivity\u2009=\u200972.2%, specificity\u200964.7%). Poor response prediction showed moderate accuracy (AUC\u2009=\u20090.662).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NIC values show excellent interobserver agreement and can predict treatment response to NARC in EC, particularly for adenocarcinomas, where lower NIC values are linked to better outcomes. While NIC provides good predictive value, further studies with larger sample sizes are needed to confirm these findings and explore additional factors influencing outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Does photon-counting CT-derived iodine concentration correlate with key histopathological features in esophageal cancer and predict response to neoadjuvant radiochemotherapy?<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Photon-counting CT\u2013derived normalized iodine concentration in esophageal adenocarcinoma moderately predicted treatment response, despite no correlation with tumor grade or Ki-67<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Normalized iodine concentration values from photon-counting CT, obtained during routine staging exams, offer an objective method for predicting treatment response in esophageal adenocarcinoma, enabling more precise therapy planning and personalized patient management<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-025-11683-1","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:00:59Z","timestamp":1748012459000},"page":"6928-6935","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Photon-counting computed tomography in esophageal cancer: correlation of iodine concentration with histopathology and treatment response to neoadjuvant radiochemotherapy"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-1295","authenticated-orcid":false,"given":"Nina Pauline","family":"Haag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Bodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Robert","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius Henning","family":"Niehoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saher","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raihanatou Ina","family":"Danebrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich Klaus","family":"Fetzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Borggrefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wienke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Surov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"11683_CR1","unstructured":"Ferlay JEM, Lam F, Laversanne M et al (2024) Cancer today: oesophagus. International Agency for Research on Cancer, Global Cancer Observatory. Available via https:\/\/gco.iarc.who.int\/today. Accessed 12 Oct 2024"},{"key":"11683_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A et al (2022) Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:992\u20131004","journal-title":"Ann Oncol"},{"key":"11683_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diii.2022.11.003","volume":"104","author":"J Greffier","year":"2023","unstructured":"Greffier J, Villani N, Defez D, Dabli D, Si-Mohamed S (2023) Spectral CT imaging: technical principles of dual-energy CT and multi-energy photon-counting CT. Diagn Interv Imaging 104:167\u2013177","journal-title":"Diagn Interv Imaging"},{"key":"11683_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/RLI.0000000000000980","volume":"58","author":"T Flohr","year":"2023","unstructured":"Flohr T, Schmidt B (2023) Technical basics and clinical benefits of photon-counting CT. Invest Radiol 58:441\u2013450","journal-title":"Invest Radiol"},{"key":"11683_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5058-2","volume":"18","author":"X Ge","year":"2018","unstructured":"Ge X, Yu J, Wang Z et al (2018) Comparative study of dual energy CT iodine imaging and standardized concentrations before and after chemoradiotherapy for esophageal cancer. BMC Cancer 18:1120","journal-title":"BMC Cancer"},{"key":"11683_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109423","volume":"134","author":"D Zopfs","year":"2021","unstructured":"Zopfs D, Gro\u00dfe Hokamp N, Reimer R et al (2021) Value of spectral detector CT for pretherapeutic, locoregional assessment of esophageal cancer. Eur J Radiol 134:109423","journal-title":"Eur J Radiol"},{"key":"11683_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-023-01068-5","volume":"23","author":"Y Wang","year":"2023","unstructured":"Wang Y, Tian W, Tian S, He L, Xia J, Zhang J (2023) Spectral CT\u2014a new supplementary method for preoperative assessment of pathological grades of esophageal squamous cell carcinoma. BMC Med Imaging 23:110","journal-title":"BMC Med Imaging"},{"key":"11683_CR8","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1016\/j.acra.2024.02.006","volume":"31","author":"A Surov","year":"2024","unstructured":"Surov A, Diallo-Danebrock R, Radi A et al (2024) Photon counting computed tomography in rectal cancer: associations between iodine concentration, histopathology and treatment response: a pilot study. Acad Radiol 31:3620\u20133626","journal-title":"Acad Radiol"},{"key":"11683_CR9","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.acra.2023.08.024","volume":"31","author":"Y Wang","year":"2024","unstructured":"Wang Y, Hu H, Ban X et al (2024) Evaluation of quantitative dual-energy computed tomography parameters for differentiation of parotid gland tumors. Acad Radiol 31:2027\u20132038","journal-title":"Acad Radiol"},{"key":"11683_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00428-017-2232-x","volume":"472","author":"R Langer","year":"2018","unstructured":"Langer R, Becker K (2018) Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch 472:175\u2013186","journal-title":"Virchows Arch"},{"key":"11683_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-020-00370-7","volume":"21","author":"X Wang","year":"2021","unstructured":"Wang X, Liu D, Zeng X et al (2021) Dual-energy CT quantitative parameters for evaluating immunohistochemical biomarkers of invasive breast cancer. Cancer Imaging 21:4","journal-title":"Cancer Imaging"},{"key":"11683_CR12","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1007\/s00330-019-06144-5","volume":"29","author":"J Wu","year":"2019","unstructured":"Wu J, Lv Y, Wang N et al (2019) The value of single-source dual-energy CT imaging for discriminating microsatellite instability from microsatellite stability human colorectal cancer. Eur Radiol 29:3782\u20133790","journal-title":"Eur Radiol"},{"key":"11683_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-017-0232-5","volume":"36","author":"C Wang","year":"2017","unstructured":"Wang C, Wang J, Chen Z, Gao Y, He J (2017) Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review. Chin J Cancer 36:65","journal-title":"Chin J Cancer"},{"key":"11683_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05291-8","volume":"22","author":"Y Ruan","year":"2024","unstructured":"Ruan Y, Ma Y, Ma M et al (2024) Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. J Transl Med 22:471","journal-title":"J Transl Med"},{"key":"11683_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33702","volume":"10","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ma Z, Bao Y et al (2024) Integrating MR radiomics and dynamic hematological factors predicts pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. Heliyon 10:e33702","journal-title":"Heliyon"},{"key":"11683_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2576563","volume":"2020","author":"C Liu","year":"2020","unstructured":"Liu C, Sun R, Wang J et al (2020) Combination of DCE-MRI and DWI in predicting the treatment effect of concurrent chemoradiotherapy in esophageal carcinoma. Biomed Res Int 2020:2576563","journal-title":"Biomed Res Int"},{"key":"11683_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2967\/jnumed.116.180299","volume":"58","author":"RJ Beukinga","year":"2017","unstructured":"Beukinga RJ, Hulshoff JB, van Dijk LV et al (2017) Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer with textural features derived from pretreatment (18)F-FDG PET\/CT imaging. J Nucl Med 58:723\u2013729","journal-title":"J Nucl Med"},{"key":"11683_CR18","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1007\/s00330-020-07439-8","volume":"31","author":"RJ Beukinga","year":"2021","unstructured":"Beukinga RJ, Wang D, Karrenbeld A et al (2021) Addition of HER2 and CD44 to (18)F-FDG PET-based clinico-radiomic models enhances prediction of neoadjuvant chemoradiotherapy response in esophageal cancer. Eur Radiol 31:3306\u20133314","journal-title":"Eur Radiol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11683-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11683-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11683-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:02:29Z","timestamp":1761627749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11683-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["11683"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11683-1","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Prof. Jan Borggrefe (Jan.borggrefe@muehlenkreiskliniken.de).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: N.P.H.: former employee of Siemens Healthineers USA. P.B.: no conflicts of interest. J.R.K.: speaker for GE Healthcare, Clinical Advisory Board Membership for Siemens Healthineers. J.B.: institutional research agreement with Siemens Healthineers; honoraria from Siemens Healthineers and Philips Healthcare. The remaining authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Study subjects or cohorts have not been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}